Synergistic effects of Zoledronic acid and Quercetin in vitro on breast cancer cells migration, proliferation and viability
Keywords:
Anticancer therapy, Metastasis, Breast cancerAbstract
Background and aim of the work: Quercetin: a natural bioactive molecule has showed promise in cancer prevention and treatment. It is used for various cancers including breast cancer. The bisphosphonate Zoledronic acid (ZA); has recently come into therapeutic use. Despite the introduction of several medicinal techniques, breast cancer remains the most common uncurable cancer in women. Given this, the current study aims to elucidate the synergistic antitumor interaction between quercetin and zoledronic acid; both of which have anti-proliferative and anti-metastatic capabilities , notably targeting fatty acid synthesis and cholesterol synthesis in breast cancer cells in vitro.
Research design and methods: Human breast cancer cell lines MCF-7 and MDA-MB-231 were treated with a quercetin, ZA, or their combination. Quercetin was applied at concentrations of 480, 240, 120, 60, 30, and 10 μM, and ZA at 360, 160, 80, 40, 20, and 10 μM. Combination treatments were applied using 80:80, 180:80, and 80:160 μM for MCF-7 cells, and 90:171, 180:171, 90:340 μM for MDA-MB-231 cells. Cell proliferation was assessed using the MTT cytotoxicity assay. RT-PCR was performed to analyze the expression of genes linked to apoptosis, clone creation, and cell migration.
Results: The quercetin-ZA combination induced Bcl-2-independent apoptosis and significantly inhibited cell growth.. The combined treatment was more effective than either medication alone after 72 hours, with IC50 values of 80:160 μM for MCF7 (p=0.0021) and 90:171 μM for MDA-MB-231 cells (p=0.0161). Self-renewal and clonogenic tumor development were markedly inhibited after 3-hour combination treatment. Moreover, MCF7 and MDA-MB 231 cell invasiveness was significantly decreased from 24 to 72 h compared with untreated cells.
Conclusions: The quercetin-ZA combination synergistically suppressed MCF-7 and MDA-MB-231 breast cancer cells, reducing migration and self-renewal. These findings highlighted their potential adjuvant effects on conventional treatments of breast cancer.
References
1. Burguin A, Diorio C, Durocher F. Breast cancer treatments: Updates and new challenges. J Pers Med. 2021;11(8):758. doi: 10.3390/jpm11080808
2. Song X, Wei C, Li X. The Signaling Pathways Associated With Breast Cancer Bone Metastasis. Front Oncol. 2022;12:864501. doi: 10.3389/fonc.2022.855609
3. Qiao H, Wang TY, Yan W, Qin A, Fan QM, Han XG, et al. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro. Acta Pharmacol Sin. 2015;36(9):1085-98. doi: 10.1038/aps.2015.42
4. Massi A, Bortolini O, Ragno D, Bernardi T, Sacchetti G, Tacchini M, et al. Research progress in the modification of quercetin leading to anticancer agents. Molecules. 2017;22(8):1273. doi: 10.3390/molecules22081270
5. Wang B, Zhan Y, Yan L, Hao D. How zoledronic acid improves osteoporosis by acting on osteoclasts. Front Pharmacol. 2022;13:1019825. doi : 10.3389/fphar.2022.961941
6. Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, et al. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int. 2012;12:48. doi: 10.1186/1475-2867-12-48
7. Ulukaya E, Karakas D, Dimas K. Tumor chemosensitivity assays are helpful for personalized Cytotoxic treatments in cancer patients. Medicina (Kaunas). 2021;57(2):131. doi: 10.3390/medicina57060636
8. Reyes-Farias M, Carrasco-Pozo C. The anti-cancer effect of quercetin: Molecular implications in cancer metabolism. Int J Mol Sci. 2019;20(13):3134. doi: 10.3390/ijms20133177
9. Lupu R, Menendez J. Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents? Curr Pharm Biotechnol. 2006;7(6):483-94. doi: 10.2174/138920106779116928
10. Lupien LE, Dunkley EM, Maloy MJ, Lehner IB, Foisey MG, Ouellette ME, et al. An inhibitor of fatty acid synthase thioesterase domain with improved cytotoxicity against breast cancer cells and stability in plasma. J Pharmacol Exp Ther. 2019;370(2):147-58. doi: 10.1124/jpet.119.258947
11. Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022-43. doi: 10.18632/oncotarget.16723
12. Li N, Sun C, Zhou B, Xing H, Ma D, Chen G, et al. Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. PLoS One. 2014;9(7):e100367. doi: 10.1371/journal.pone.0100314
13. Weiskirchen S, Schröder SK, Buhl EM, Weiskirchen R. A Beginner’s Guide to Cell Culture: Practical Advice for Preventing Needless Problems. Cells. 2023;12(5):682. doi: 10.3390/cells12050682
14. Jhamb SK, Goyal A, Pandey A, Bhowmik A. A review of cytotoxicity testing methods and in vitro study of biodegradable Mg-1%Sn-2%HA composite by elution method. J Mater Sci Mater Med. 2025;36(1):15. doi: 10.1007/s10856-025-06951-x
15. Bechtold B, Clarke J. Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy. Expert Opin Drug Metab Toxicol. 2021;17(4):397-412. doi: 10.1080/17425255.2021.1867105
16. Rouhrazi H, Turgan N, Oktem G. Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis. Biotech Histochem. 2018;93(2):77-88. doi: 10.1080/10520295.2017.1387286
17. Haller F, Kulle B, Schwager S, Gunawan B, Von Heydebreck A, Sültmann H, et al. Equivalence test in quantitative reverse transcription polymerase chain reaction: Confirmation of reference genes suitable for normalization. Anal Biochem. 2004;335(1):1-9. doi: 10.1016/j.ab.2004.08.024
18. Brix N, Samaga D, Hennel R, Gehr K, Zitzelsberger H, Lauber K. The clonogenic assay: robustness of plating efficiency-based analysis is strongly compromised by cellular cooperation. Radiat Oncol. 2020;15(1):248. doi: 10.1186/s13014-020-01697-y
19. Yarrow JC, Perlman ZE, Westwood NJ, Mitchison TJ. A high-throughput cell migration assay using scratch wound healing, a comparison of image-based readout methods. BMC Biotechnol. 2004;4:21. doi: 10.1186/1472-6750-4-21
20. Rhman MA, Devnarain N, Khan R, Owira PMO. Synergism Potentiates Oxidative Antiproliferative Effects of Naringenin and Quercetin in MCF-7 Breast Cancer Cells. Molecules. 2022;27(13):4214. doi: 10.3390/nu14163437
21. Kundur S. Synergistic anticancer action of quercetin and curcumin against triple-negative breast cancer cell lines. J Cell Physiol. 2019;234(7):11103-18. doi: 10.1002/jcp.27761
22. Asgharian P, Tazekand AP, Hosseini K, Forouhandeh H, Ghasemnejad T. Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets. Cancer Cell Int. 2022;22(1):257. doi: 10.1186/s12935-022-02677-w
23. Kars MD, İşcan ÖD. In Vitro Evaluation of Zoledronic Acid Resistance Developed in MCF-7 Cells. Anticancer Res. 2007;27(6B):4031-7. PMID: 18225567
24. Wang R, Yang L, Li S, Ye D, Yang L, Liu Q, Zhao Z, Cai Q, Tan J, Li X. Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM). Med Sci Monit. 2018 Jan 21;24:412-420. doi: 10.12659/msm.908022. PMID: 29353288; PMCID: PMC5788241
25. Lu J, Wang Z. Quercetin Inhibits the Migration and Invasion of HCCLM3 Cells by Suppressing the Expression of p-Akt1, Matrix Metalloproteinase (MMP). Med Sci Monit. 2018;24:2583-9. doi: 10.12659/MSM.906172
26. Adchariyasakulchai P, Sakunrangsit N, Chokyakorn S, Suksanong C, Ketchart W. Anticancer effect of zoledronic acid in endocrine-resistant breast cancer cells via HER-2 signaling. Biomed Pharmacother. 2024;171: 116142. doi: 10.1016/j.biopha.2024.116142
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
